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Abstract
Herein we describe a case of febrile non-hemolytic reaction 
(FNHTR) in a 64-year-old male 20 min after the transfusion of 
one red blood cell unit. 20 days prior the patient had under-
gone an allogeneic hematopoietic stem cell transplantation 
(HCT) from an unrelated donor with minor ABO disparity. 
The patient had been treated for plasma cell myeloma with 
multiple transfusions in the past, but no transfusion reac-
tions or alloimmunization had been reported. 
© 2019 S. Karger GmbH, Freiburg
Introduction
The Diego (Di) blood group system comprises 22 an-
tigens located on the band 3 protein [1, 2], most of which 
are low-prevalence antigens. Dia, a low-prevalence blood 
group itself, is expressed in only 0.01% of Caucasians but 
is more frequent in some populations, i.e. in subjects of 
Asian and South American descent. Rates of alloimmu-
nization against Dia in multitransfused patients in Brazil, 
for example, have been estimated to be as high as 3.6%, 
due to the higher frequency of the Dia antigen in Brazilian 
blood donors [3, 4]. 
Case Report
We describe a transfusion reaction that was classified as febrile 
non-hemolytic (FNHTR) in a Swiss 64-year-old male patient regu-
larly transfused during treatment for plasma cell myeloma. 20 days 
prior to the event, he had undergone allogeneic hematopoietic 
stem cell transplantation from a matched unrelated donor with 
minor ABO disparity. Despite a long-standing medical history, in-
cluding autologous stem cell transplantation in Brazil in 2011, no 
transfusion reactions or alloimmunization had so far been report-
ed in the patient’s history. 
The symptoms of the transfusion reaction developed shortly 
after initiation of the transfusion of a red blood cell (RBC) unit, 
and included an increase of the core temperature to 38.2 ° C, slight 
shivers, and a temporary drop of the oxygen saturation with no 
signs of bronchospasm on auscultation. No chest X-ray was per-
formed. The symptoms were responsive to acetaminophen, clem-
astine, pethidine, and methylprednisolone. The RBC unit was the 
only blood product given on this day and was issued based on a 
negative type and screen, according to internal routine procedures. 
Of interest, the blood donor of the involved blood product was a 
21-year-old Swiss male whose mother is of Chinese origin. 
Laboratory investigations showed a slight increase of LDH (273 
U/l; upper cut-off limit 225 U/l) and of bilirubin (from 8 μmol/l to 
15 µmol/l) that remained however within the normal range (<24 
μmol/l). A haptoglobin measurement was not performed. Of note, 
the hemoglobin level dropped from a pre-transfusion value of 73 
g/l to a post-transfusion level of 67 g/l, suggesting a shortened sur-
vival time of the transfused erythrocytes.
On immunohematological workup, the alloantibody identifica-
tion test (ID-DiaPanel; Bio Rad, Cressier, Switzerland) as well as 
the direct antiglobulin tests before and after transfusion were nega-
tive. However, the crossmatch (gel-based indirect antiglobulin test) 
performed on both a pre-transfusion and post-transfusion sample 
showed incompatibility with the RBC unit administered (3+ and 
2+ respectively), suggesting the presence of an alloantibody against 
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a low-prevalence RBC antigen in the patient’s serum. A post-trans-
fusion serum sample of the patient and a sample of the involved 
RBC unit were sent to the Swiss immunohematology reference lab-
oratory for further investigation. An anti-Dia alloantibody in the 
patient‘s serum could be identified using an extended panel of test 
erythrocytes, and the presence of the Dia antigen on the surface of 
the transfused RBC was confirmed by serological determination. 
In order to evaluate the potential clinical significance of the al-
loantibody, a monocyte monolayer assay (MMA) was performed. 
In this assay, test RBCs expressing the antigen in question are sen-
sitized with the recipient’s serum before being incubated with a 
culture of monocytes harvested from a healthy donor. The degree 
of erythrophagocytosis (Monocyte Index) is then evaluated by mi-
croscopy. In our case, the MMA showed a Monocyte Index of 46%, 
highly indicative of the alloantibody’s clinical significance (>5% is 
considered as clinically significant) (fig. 1). 
In the following weeks, all RBC units issued to the patient were 
tested by crossmatch, and all subsequent transfusion episodes were 
uneventful.
Discussion
This case is illustrative of immunohematology issues that 
can be relevant in daily transfusion practice. First, it pro-
vides an example of type and screen failure in detecting clin-
ically relevant antibodies directed against low-frequency an-
tigens. Anti-Dia alloantibodies are likely to escape antibody 
screening in most European transfusion laboratories, be-
cause usually no Dia-positive RBCs are included in the pan-
els used for type and screen and for alloantibody identifica-
tion, and because many centers, like ours, issue compatible 
RBC units based on negative results of type and screen with-
out direct crossmatch. Second, our case highlights the pos-
sible implications of the ethnic disparity between blood do-
nors and recipients of transfusions. The RBC transfusions 
received by our patient some years before in Brazil are very 
likely responsible for the development of the anti-Dia allo-
antibody. The ethnical background of the blood donor im-
plicated in the transfusion reaction (mother of Asian de-
scent) explains the presence of Dia antigens on the surface 
of his erythrocytes, which boostered the alloantibody. 
Transfusions of Dia-incompatible RBC units were de-
scribed to cause very variable clinical manifestations, 
ranging from uneventful to severe or delayed transfusion 
reactions [5, 6]. In our case, due to the mild respiratory 
symptoms and the absence of overt hemolysis, the trans-
fusion reaction was classified as a FNHTR, when in fact 
an immediate, albeit mild hemolytic reaction contributed 
to the findings, as demonstrated by the lack of adequate 
hemoglobin increase after the transfusion and markedly 
increased phagocytic index in the MMA.
The MMA has proven to be a reliable in vitro tool for 
predicting the fate of transfused RBCs and for estimating 
the risk for a hemolytic transfusion reaction in alloimmu-
nized subjects and in cases of materno-fetal blood group 
incompatibility [7]. Interestingly, in our patient a clear dis-
crepancy was observed between the strongly reactive result 
of the MMA and the mild clinical manifestations. It is well 
described that a negative MMA reliably excludes the pres-
ence of clinically relevant alloantibodies, but, as demon-
strated in our case, the strength of MMA reactivity seems 
not necessarily to correlate with the severity of symptoms.
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Fig. 1. The photos illustrate erythrophago-
cytosis by monocytes.
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